Catalyst Biosciences Inc. has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.   “We have been exploring strategic alternatives to monetize our assets and maximize value for our shareholders. This sale is part of the ongoing strategic process that we announced in February to explore alternatives and cr...